Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220433 | 0.93 | CSF1R (0.33) | SLC2A1ALDH1A1HTTNPSR1KMT2A | |
| SCHEMBL2741112 | 0.90 | CSF1R (0.32) | ALDH1A1HTTNPSR1L3MBTL1KMT2A | |
| SCHEMBL223144 | 0.87 | ATM (0.36) | ALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL223143 | 0.87 | ATM (0.36) | ALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL222324 | 0.85 | NPC1 (0.33) | NPC1LMNASMN1; SMN2 | |
| SCHEMBL222202 | 0.85 | NPC1 (0.33) | NPC1RAB9ALMNASMN1; SMN2KMT2A | |
| SCHEMBL13599616 | 0.84 | MAOB (0.39) | KDM4EALDH1A1HTTNPSR1LMNA | |
| SCHEMBL2789383 | 0.83 | CSF1R (0.30) | — | |
| SCHEMBL28578189 | 0.83 | KMT2A (0.36) | KDM4EALDH1A1HTTNPSR1LMNA | |
| SCHEMBL222304 | 0.83 | ALDH1A1 (0.36) | KDM4EALDH1A1HTTNPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431039-B2 | Mesogenic stabilizers | TRANSITIONS OPTICAL, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120002141-A1 | MESOGENIC STABILIZERS | TRANSITIONS OPTICAL, INC. (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120002141-A1 | MESOGENIC STABILIZERS | BMI1, METTL14, PYM1 | SLC2A1 4003/4885KDM4E 376/4885NPC1 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.